María José Morlán-Coarasa1, María Teresa Arias-Loste2, Víctor Ortiz-García de la Foz3, Obdulia Martínez-García3, Carmen Alonso-Martín2, Javier Crespo2, Manuel Romero-Gómez4, Emilio Fábrega2, Benedicto Crespo-Facorro5. 1. Department of Medicine and Psychiatry. Psychiatry Unit. IDIVAL, Instituto de Investigación Valdecilla, Hospital Universitario Marques de Valdecilla, 39008, Santander, Spain. josetamc@hotmail.com. 2. Gastroenterology and Hepatology Department. Infection, Immunity and Digestive Pathology Group. IDIVAL, Instituto de Investigación Valdecilla, Hospital Universitario Marques de Valdecilla, 39008, Santander, Spain. 3. Department of Medicine and Psychiatry. Psychiatry Unit. IDIVAL, Instituto de Investigación Valdecilla; Instituto de Salud Carlos III, 3-CIBERSAM, Centro Investigación Biomédica en Red Salud Mental, Hospital Universitario Marques de Valdecilla, 39008, Santander, Spain. 4. UCM Digestive Diseases and Ciberehd, University of Seville, Hospital Universitario de Valme, 41004, Sevilla, Spain. 5. Department of Medicine and Psychiatry. Psychiatry Unit. IDIVAL, Instituto de Investigación Valdecilla; Instituto de Salud Carlos III, 3-CIBERSAM, Centro Investigación Biomédica en Red Salud Mental, Hospital Universitario Marques de Valdecilla, 39008, Santander, Spain. benedicto.crespo@unican.es.
Abstract
RATIONALE: Patients with schizophrenia spectrum disorders have increased morbidity and mortality, largely due to cardiovascular disease, which is associated with antipsychotic treatment. OBJECTIVES: Because of the link between cardiometabolic risk, non-alcoholic fatty liver disease (NAFLD), and antipsychotics, we aimed to investigate the development of NAFLD during the first 3 years of antipsychotic treatment in first episode non-affective psychosis patients. RESULTS:A sample of 191 subjects was included in final analyses, randomly assigned to aripiprazole (N = 83), risperidone (N = 12), quetiapine (N = 46), and ziprasidone (N = 50). At intake, 180 patients were antipsychotic naïve. The NAFLD fibrosis score, FIB-4 score, and the fatty liver index (FLI) were calculated at baseline, at 3 months, and then yearly for 3 years. None of the patients showed significant liver fibrosis according to the mentioned scores at baseline, prior to randomization. At 3 years follow-up, 25.1 % individuals showed a FLI score ≥60, which is a predictor of steatosis. Of the individuals considered indeterminate at baseline, 64.7 % developed a FLI score ≥60 and only 16.6 % who had a FLI score <30 at baseline, showed a FLI score predictor of steatosis at endpoint. The FLI score ≥60 at endpoint was associated with an increase of more than 7 % of the body mass index (FLI score ≥ 60, 91.7 %; FLI < 60, 55.9 %; p < 0.001), increased triglyceride levels (FLI score ≥ 60, 54.2 %; FLI < 60, 5.6 %; p < 0.001), decreased HDL levels (FLI score ≥ 60, 41.7 %; FLI < 60, 17.5 %; p = 0.001), hypertension (FLI score ≥ 60, 19.5 %; FLI < 60, 4.5 %; p = 0.002), and waist circumference increase (steatosis 68.8 %; FLI < 60, 14.0 %; p < 0.001). CONCLUSIONS: Our results support the importance of assessing the potential development of NAFLD in schizophrenia spectrum patients receiving antipsychotic medication.
RCT Entities:
RATIONALE: Patients with schizophrenia spectrum disorders have increased morbidity and mortality, largely due to cardiovascular disease, which is associated with antipsychotic treatment. OBJECTIVES: Because of the link between cardiometabolic risk, non-alcoholic fatty liver disease (NAFLD), and antipsychotics, we aimed to investigate the development of NAFLD during the first 3 years of antipsychotic treatment in first episode non-affective psychosispatients. RESULTS: A sample of 191 subjects was included in final analyses, randomly assigned to aripiprazole (N = 83), risperidone (N = 12), quetiapine (N = 46), and ziprasidone (N = 50). At intake, 180 patients were antipsychotic naïve. The NAFLD fibrosis score, FIB-4 score, and the fatty liver index (FLI) were calculated at baseline, at 3 months, and then yearly for 3 years. None of the patients showed significant liver fibrosis according to the mentioned scores at baseline, prior to randomization. At 3 years follow-up, 25.1 % individuals showed a FLI score ≥60, which is a predictor of steatosis. Of the individuals considered indeterminate at baseline, 64.7 % developed a FLI score ≥60 and only 16.6 % who had a FLI score <30 at baseline, showed a FLI score predictor of steatosis at endpoint. The FLI score ≥60 at endpoint was associated with an increase of more than 7 % of the body mass index (FLI score ≥ 60, 91.7 %; FLI < 60, 55.9 %; p < 0.001), increased triglyceride levels (FLI score ≥ 60, 54.2 %; FLI < 60, 5.6 %; p < 0.001), decreased HDL levels (FLI score ≥ 60, 41.7 %; FLI < 60, 17.5 %; p = 0.001), hypertension (FLI score ≥ 60, 19.5 %; FLI < 60, 4.5 %; p = 0.002), and waist circumference increase (steatosis 68.8 %; FLI < 60, 14.0 %; p < 0.001). CONCLUSIONS: Our results support the importance of assessing the potential development of NAFLD in schizophrenia spectrum patients receiving antipsychotic medication.
Authors: Marc De Hert; Johan Detraux; Ruud van Winkel; Weiping Yu; Christoph U Correll Journal: Nat Rev Endocrinol Date: 2011-10-18 Impact factor: 43.330
Authors: Richard K Sterling; Eduardo Lissen; Nathan Clumeck; Ricard Sola; Mendes Cassia Correa; Julio Montaner; Mark S Sulkowski; Francesca J Torriani; Doug T Dieterich; David L Thomas; Diethelm Messinger; Mark Nelson Journal: Hepatology Date: 2006-06 Impact factor: 17.425
Authors: Christoph U Correll; Delbert G Robinson; Nina R Schooler; Mary F Brunette; Kim T Mueser; Robert A Rosenheck; Patricia Marcy; Jean Addington; Sue E Estroff; James Robinson; David L Penn; Susan Azrin; Amy Goldstein; Joanne Severe; Robert Heinssen; John M Kane Journal: JAMA Psychiatry Date: 2014-12-01 Impact factor: 21.596
Authors: Paul Angulo; Jason M Hui; Giulio Marchesini; Ellisabetta Bugianesi; Jacob George; Geoffrey C Farrell; Felicity Enders; Sushma Saksena; Alastair D Burt; John P Bida; Keith Lindor; Schuyler O Sanderson; Marco Lenzi; Leon A Adams; James Kench; Terry M Therneau; Christopher P Day Journal: Hepatology Date: 2007-04 Impact factor: 17.425
Authors: Benjamin I Perry; Frederik Vandenberghe; Nathalia Garrido-Torres; Emanuele F Osimo; Marianna Piras; Javier Vazquez-Bourgon; Rachel Upthegrove; Claire Grosu; Victor Ortiz-Garcia De La Foz; Peter B Jones; Nermine Laaboub; Miguel Ruiz-Veguilla; Jan Stochl; Celine Dubath; Manuel Canal-Rivero; Pavan Mallikarjun; Aurélie Reymond-Delacrétaz; Nicolas Ansermot; Emilio Fernandez-Egea; Severine Crettol; Franziska Gamma; Kerstin J Plessen; Philippe Conus; Golam M Khandaker; Graham K Murray; Chin B Eap; Benedicto Crespo-Facorro Journal: Lancet Reg Health Eur Date: 2022-08-19
Authors: Marco Solmi; Andrea Murru; Isabella Pacchiarotti; Juan Undurraga; Nicola Veronese; Michele Fornaro; Brendon Stubbs; Francesco Monaco; Eduard Vieta; Mary V Seeman; Christoph U Correll; André F Carvalho Journal: Ther Clin Risk Manag Date: 2017-06-29 Impact factor: 2.423
Authors: Óscar Soto-Angona; Gerard Anmella; María José Valdés-Florido; Nieves De Uribe-Viloria; Andre F Carvalho; Brenda W J H Penninx; Michael Berk Journal: BMC Med Date: 2020-10-01 Impact factor: 8.775
Authors: Emanuele F Osimo; Mark Sweeney; Antonio de Marvao; Alaine Berry; Ben Statton; Benjamin I Perry; Toby Pillinger; Thomas Whitehurst; Stuart A Cook; Declan P O'Regan; E Louise Thomas; Oliver D Howes Journal: Transl Psychiatry Date: 2021-12-06 Impact factor: 6.222